曲伏前列素联合噻吗洛尔治疗开角型青光眼的临床疗效

目的 观察曲伏前列素联合噻吗洛尔治疗开角型青光眼的临床疗效.方法 收集我院眼科2011年1月～ 2016年1月收治的开角型青光眼的患者120例,随机分为试验组和对照组,每组60例,试验组患者给予曲伏前列素联合噻吗洛尔治疗,对照组给予噻吗洛尔滴眼液治疗,比较两组患者的治疗效果.结果 试验组治疗有效率为96.7％,高于对照组的86.7％ (P ＜0.05);治疗后试验组眼压低于对照组(P＜0.05);与治疗前相比,治疗后两组眼压均降低,且试验组降低的更为显著(P＜0.05).结论 曲伏前列素联合噻吗洛尔治疗开角型青光眼疗效显著,可有效降低患者的眼压,缓解患者的不适,安全可靠,值得推广.     

拉坦前列素与噻吗洛尔不同联用方案治疗原发性开角型青光眼的临床观察

目的:观察拉坦前列素与噻吗洛尔不同联用方案治疗原发性开角型青光眼(POAG)的临床疗效与安全性。方法:采用2×2自身交叉对照方案,选择2014年1月-2016年11月在三亚市人民医院接受治疗的50例POAG患者,按随机数字表法分为A、B两个治疗顺序组,各25例。A组患者先行传统用药方案(拉坦前列素滴眼液每晚1次,每次1滴+马来酸噻吗洛尔滴眼液早晚各滴1次,每次1滴),治疗8周后,经48 h洗脱期,再行改进用药方案(拉坦前列素滴眼液每晚1次,每次1滴+马来酸噻吗洛尔滴眼液每日早上1次,每次1滴)治疗8周;B组患者则先行改进治疗方案治疗,治疗8周后,经48 h洗脱期,再行传统治疗方案治疗8周。比较两种用药方案患者用药前后24 h平均眼压、峰值眼压、谷值眼压及眼压波动值,并记录其眼部血流动力学[最大舒张末期血流速度(EDV)、最大收缩期峰值血流速度(PSV)、阻力指数(RI)]及不良反应发生情况。结果:两种用药方案治疗后,患者24 h平均眼压、峰值眼压、谷值眼压、眼压波动值及RI均显著低于治疗前,EDV、PSV均显著高于治疗前,差异均有统计学意义(P<0.05),但两组间比较差异均无统计学意义(P>0.05)。改进用药方案患者的不良反应总发生率显著低于传统用药方案(4.0%vs.22.0%),差异均有统计学意义(P<0.05)。结论:将拉坦前列素联合噻吗洛尔的传统联用方案中的噻吗洛尔早晚2次用药改为早上1次用药,不改变其疗效,但用药不良反应有所减少。     

曲伏前列素滴眼液治疗原发性开角型青光眼的有效性及安全性分析

目的:分析曲伏前列素滴眼液治疗原发性开角型青光眼的有效性及安全性.方法:原发性开角型青光眼患者46例(82眼),随机分为实验组和对照组,对照组23例(40眼)采用噻吗洛尔滴眼液治疗,实验组23例(42眼)采用曲伏前列素滴眼液治疗,比较两组治疗效果及不良反应情况.结果:治疗前,两组眼压及视力无明显差异(P>0.05);经过治疗,实验组眼压低于对照组,且视力高于对照组(P<0.01);两组在治疗过程中的不良反应发生率无明显差异(P>0.05).结论:曲伏前列素滴眼液治疗原发性开角型青光眼,能够有效降低眼压,改善视力,且无不良反应.     

噻吗洛尔与拉坦前列素降眼压疗效对比分析

青光眼的治疗主要是降低眼压,目前降眼压药物多数都针对房水循环的不同环节抑止房水生成或增加房水流出,达到降眼压的目的.通常选用的降眼压药有β受体阻滞剂,噻吗洛尔是这类药物中最常用的.本文选取开角型青光眼56例,随机分成两组,采用噻吗洛尔和拉坦前列素治疗,对比分析其疗效和安全性.     

拉坦前列素及噻吗心安治疗开角型青光眼的疗效观察及安全性评估

目的 研究拉坦前列素及噻吗心安治疗开角型青光眼的疗效及安全性.方法 将120例开角型青光眼患者纳入研究对象,随机分为给予拉坦前列素联合噻吗心安治疗的观察组和单独给予噻吗心安治疗的对照组,检测视野缺损情况、视网膜神经纤维层厚度并观察不良反应例数.结果 （1）观察组患者的上方视野（4.9±0.8） dB、下方视野（5.1±0.9）dB、颞侧视野（7.2±1.3）dB、鼻侧视野缺损（6.9± 1.1） dB均明显低于对照组（P＜0.05）;（2）观察组患者的上方视野（92.3±13.2）μm、下方视野（90.8± 12.1） μm、颞侧视野（74.2±10.3）μm、鼻侧视野RNFL厚度（70.8±12.3）μm均明显高于对照组（P＜0.05）;（3）两组患者发生不良反应例数比较差异无统计学意义（P＞ 0.05）.结论 拉坦前列素及噻吗心安治疗开角型青光眼有助于改善视野缺损和视网膜神经纤维层厚度,且保证相当的安全性,具有积极的临床价值.     

曲伏前列素与噻吗洛尔滴眼液治疗老年青光眼临床疗效与安全性观察

目的观察曲伏前列素与噻吗洛尔滴眼液治疗老年青光眼临床疗效与安全性差异,优化青光眼治疗方案。方法将88例青光眼患者分为曲伏前列素组44例(80眼)与噻吗洛尔组44例(76眼),分别滴用曲伏前列素与噻吗洛尔滴眼液,治疗4周,观察治疗前后眼压、昼夜眼压差、视野缺损,记录不良反应发生情况。结果 (1)曲伏前列素、噻吗洛尔治疗后平均眼压、昼夜眼压差、视野缺损均较治疗前明显降低(P0.01或P0.05),治疗后曲伏前列素组与噻吗洛尔组平均眼压、昼夜眼压差、视野缺损、平均眼压下降值分别为(19.23±2.43)比(23.28±3.54),(4.03±0.78)比(5.54±0.86),(6.82±0.34)比(8.03±0.83),(8.25±1.31)比(5.27±0.86),曲伏前列素组平均眼压、昼夜眼压差、视野缺损均较对照组明显降低,平均眼压下降值较对照组明显升高(均P0.05);(2)曲伏前列素组和噻吗洛尔组不良反应发生率分别为20%(16/80)和18.42%(14/76),两组不良反应差异无统计学意义(x2=0.063,P0.05)。结论曲伏前列素滴眼液是治疗老年青光眼强效、稳定和安全的药物,可作为临床老年各类青光眼的首选治疗药物。     

曲伏前列素治疗原发性开角型青光眼效果观察

目的 探讨曲伏前列素治疗原发性开角型青光眼(Primary open-angle glaucoma,POAG)的效果.方法 选择本院2020年5月至2021年6月收治的POAG患者60例,随机分为对照组和观察组各30例.对照组使用马来酸噻吗洛尔治疗,观察组使用曲伏前列素治疗.两组均连续治疗1个月.比较两组患者治疗前后视...     

曲伏前列素滴眼液与盐酸卡替洛尔滴眼液联合治疗开角型青光眼的疗效

目的：探讨曲伏前列素滴眼液与盐酸卡替洛尔滴眼液联合治疗开角型青光眼的疗效。方法选取2014年1—7月常州市第三人民医院收治的开角型青光眼患者60例,随机分为观察组与对照组,各30例。对照组患者予以盐酸卡替洛尔滴眼液治疗,观察组患者在对照组基础上加用曲伏前列素滴眼液治疗。观察两组患者治疗前后眼压、临床疗效及不良反应发生情况。结果两组患者治疗前比较,差异无统计学意义（P ﹥0.05）,治疗后4周、12周观察组患者眼压低于对照组,差异有统计学意义（ P ﹤0.05）;观察组患者总有效率高于对照组,差异有统计学意义（P ﹤0.05）;两组患者均未发生严重不良反应。结论曲伏前列素滴眼液与盐酸卡替洛尔滴眼液联合治疗开角型青光眼的疗效显著,可改善患者眼压,且不良反应小。     

拉坦前列素和噻吗洛尔滴眼液降低眼内压的对照研究

目的:观察拉坦前列素(适利达)滴眼液降低眼内压的有效性和安全性。方法:采用随机对照研究方法,拉坦前列素一日1次,0.5％噻吗洛尔一日2次,疗程1 2周,观察眼内压和不良反应。结果:适利达组和噻吗洛尔组的眼内压均显著降低(P<0.01),且两组的眼内压下降无显著性差异,两组治疗前后眼压下降值稳定。除5例结膜充血外,无明显的局部和全身性不良反应。结论:适利达是一种稳定有效的新型降眼压药物,局部反应轻微,无全身性不良反应,有望成为安全理想的一线降眼压药物。     

曲伏前列素滴眼液在原发性开角型青光眼治疗中的应用效果

目的:探究曲伏前列素滴眼液在原发性开角型青光眼治疗中的应用效果.方法:随机抽取2013年1月~2015年6月我院收治的原发性开角型青光眼患者80例(160眼),均分为两组,实验组40例(80眼)和对照组40例(80眼).对照组采用马来酸噻吗洛尔治疗,实验组采用曲伏前列素滴眼液进行治疗.对两组治疗情况、不良反应发生率、治疗前后视力、散光度及治疗前后眼压进行比较分析.结果:两组均顺利完成治疗,实验组在改善视力、眼压、散光度方面均优于对照组(P<0.05);实验组治疗效果更为理想,不良反应发生率更低,使用感更好(P<0.05),差异均具有统计学意义.结论:曲伏前列素滴眼液在原发性开角型青光眼治疗中的应用效果理想,不良反应较少,安全性更好.     

Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma

OBJECTIVE: The objective of this review was to evaluate different measures of efficacy of the intraocular pressure (IOP) lowering lipid class agents bimatoprost, latanoprost and travoprost in the treatment of primary open angle glaucoma. Study arms of timolol in trials including the above mentioned lipid class drugs were also included. METHODS: MEDLINE and EMBASE were searched for randomized clinical trials including one or more of the lipid class drugs bimatoprost, latanoprost and travoprost. The study results were pooled, and the simple, weighted IOP-lowering efficacy was compared among the lipid class drugs and timolol, where data were available. Efficacy parameters were reviewed, including mean reduction of IOP and percentage of patients achieving different levels of IOP. RESULTS: 161 articles were identified of which 42 were included in the analysis. A total of 9295 patients participated in the included trials. Based on all studies, timolol on average had a weighted mean IOP reduction of 22.2%, while latanoprost, travoprost and bimatoprost had a weighted mean IOP reduction of 26.7%, 28.7% and 30.3%, respectively. Analysis of target achievement to various IOP levels shows that bimatoprost seems more efficacious than latanoprost. The direct comparisons (head-to-head studies) also show that bimatoprost is the most efficacious treatment, however it is not conclusive whether latanoprost or travoprost is better in reducing IOP. CONCLUSIONS: This review shows that bimatoprost seems to be the most efficacious treatment in lowering IOP. Head-to-head studies confirm this.     

Analytic review of bimatoprost,latanoprost and travoprost in primary open angle glaucoma

ABSTRACT

Objective: The objective of this review was to evaluate different measures of efficacy of the intraocular pressure (IOP) lowering lipid class agents bimatoprost, latanoprost and travoprost in the treatment of primary open angle glaucoma. Study arms of timolol in trials including the above mentioned lipid class drugs were also included.

Methods: MEDLINE and EMBASE were searched for randomized clinical trials including one or more of the lipid class drugs bimatoprost, latanoprost and travoprost. The study results were pooled, and the simple, weighted IOP-lowering efficacy was compared among the lipid class drugs and timolol, where data were available. Efficacy parameters were reviewed, including mean reduction of IOP and percentage of patients achieving different levels of IOP.

Results: 161 articles were identified of which 42 were included in the analysis. A total of 9295 patients participated in the included trials. Based on all studies, timolol on average had a weighted mean IOP reduction of 22.2%, while latanoprost, travoprost and bimatoprost had a weighted mean IOP reduction of 26.7%, 28.7% and 30.3%, respectively. Analysis of target achievement to various IOP levels shows that bimatoprost seems more efficacious than latanoprost. The direct comparisons (head-to-head studies) also show that bimatoprost is the most efficacious treatment, however it is not conclusive whether latanoprost or travoprost is better in reducing IOP.

Conclusions: This review shows that bimatoprost seems to be the most efficacious treatment in lowering IOP. Head-to-head studies confirm this.     

The cost-effectiveness of bimatoprost,latanoprost and timolol in treatment of primary open angle glaucoma in five European countries

ABSTRACT

Objective: The objective of this cost-effectiveness analysis is to evaluate cost-effectiveness ratios of the intraocular pressure (IOP)-lowering agents bimatoprost, latanoprost and timolol in five major European countries: France, Germany, Italy, Spain and the UK.

Methods: The cost-effectiveness analysis is based on achievement of IOP targets between 13 and 18?mm Hg. Thus, the cost-effectiveness ratios express the costs of having one patient successfully achieving IOP target. The perspective of the analysis is that of the health care sector payer, including costs of medicine and costs of ophthalmologist visits. The time frame is first year of glaucoma treatment. Four treatment strategies are analysed: Timolol as first line with add-on latanoprost or bimatoprost if IOP targets are not met, and latanoprost and bimatoprost as first line with add-on timolol.

Results: In the UK, Spain, Italy and Germany the timolol first with add-on of bimatoprost is the least expensive treatment. This strategy dominates both strategies involving latanoprost (as add-on to timolol or as first line) in these four countries. The incremental cost-effectiveness ratio of bimatoprost first-line therapy versus timolol with add-on bimatoprost varies from each country and target (from £305 to €43 720 per patient). In France the timolol first line and latanoprost add-on is not dominated and is the cheapest alternative. The incremental cost-effectiveness ratio of timolol with add-on bimatoprost versus add-on latanoprost lies between £71 and €355 per patient depending on target (18 and 13?mm Hg, respectively).

Conclusion: First-line treatment of latanoprost is dominated in all countries. In four out of five countries the timolol first-line therapy with add-on latanoprost is also dominated. Based on this pharmacoeconomic analysis, the most costeffective strategy seems to be timolol first line with add-on bimatoprost if target is not met after 3 months.     

The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries

OBJECTIVE: The objective of this cost-effectiveness analysis is to evaluate cost-effectiveness ratios of the intraocular pressure (IOP)-lowering agents bimatoprost, latanoprost and timolol in five major European countries: France, Germany, Italy, Spain and the UK. METHODS: The cost-effectiveness analysis is based on achievement of IOP targets between 13 and 18 mm Hg. Thus, the cost-effectiveness ratios express the costs of having one patient successfully achieving IOP target. The perspective of the analysis is that of the health care sector payer, including costs of medicine and costs of ophthalmologist visits. The time frame is first year of glaucoma treatment. Four treatment strategies are analysed: Timolol as first line with add-on latanoprost or bimatoprost if IOP targets are not met, and latanoprost and bimatoprost as first line with add-on timolol. RESULTS: In the UK, Spain, Italy and Germany the timolol first with add-on of bimatoprost is the least expensive treatment. This strategy dominates both strategies involving latanoprost (as add-on to timolol or as first line) in these four countries. The incremental cost-effectiveness ratio of bimatoprost first-line therapy versus timolol with add-on bimatoprost varies from each country and target (from 305 pounds sterlings to 43,720 euros per patient). In France the timolol first line and latanoprost add-on is not dominated and is the cheapest alternative. The incremental cost-effectiveness ratio of timolol with add-on bimatoprost versus add-on latanoprost lies between 71 euros and 355 euros per patient depending on target (18 and 13 mm Hg, respectively). CONCLUSION: First-line treatment of latanoprost is dominated in all countries. In four out of five countries the timolol first-line therapy with add-on latanoprost is also dominated. Based on this pharmacoeconomic analysis, the most cost-effective strategy seems to be timolol first line with add-on bimatoprost if target is not met after 3 months.     

Comments on The cost-effectiveness of bimatoprost,latanoprost and timolol in treatment of primary open angle glaucoma in five European countries

Abstract

Objective:

The dopamine agonist rotigotine has shown efficacy and safety for the treatment of early and advanced Parkinson’s disease (PD) in controlled clinical trials. This observational study evaluated rotigotine administration in combination with other antiparkinsonian medication in routine clinical practice.     

毛果芸香碱联合拉坦前列素治疗原发性急性闭角型青光眼的疗效观察

目的探讨毛果芸香碱联合拉坦前列素治疗原发性急性闭角型青光眼的疗效及安全性。方法随机选取2014年5月—2015年1月海南医学院附属医院眼科收治的原发性急性闭角型青光眼患者92例,随机分为对照组和治疗组,每组各46例。对照组给予拉坦前列素滴眼液,1滴/次,1次/d。治疗组在对照组的基础上给药5 min后滴加硝酸毛果芸香碱滴眼液,2~3滴/次,2~4次/d。两组均连续治疗6个月。观察两组的临床疗效,同时比较两组患者治疗前后的视力、瞳孔直径、眼压、血流动力学指标舒张末期血流速度(EDV)、收缩期峰值血流速度(PSV)、血管阻力指数(RI)及不良反应。结果治疗后,对照组和治疗组的总有效率分别为82.61%、95.65%,两组比较差异有统计学意义(P0.05)。治疗1、3、6个月,两组患者的患眼视力、瞳孔直径均较同组治疗前显著改善,同组治疗前后差异具有统计学意义(P0.05);且治疗后,治疗组患者的视力、瞳孔直径改善程度明显优于同期对照组,两组比较差异具有统计学意义(P0.05)。对照组治疗3、6个月,治疗组治疗1、3、6个月的眼压与同组治疗前相比均有显著下降,且治疗组患者眼压下降情况明显优于同期对照组(P0.05);治疗1、3、6个月,治疗组患者的EDV、PSV均明显高于对照组,而RI则明显低于对照组,同组治疗前后差异有统计学意义(P0.05);且治疗组的改善程度优于对照组,两组比较差异有统计学意义(P0.05)。对照组和治疗组的不良反应发生率分别为10.87%、0.00%,两组比较差异有统计学意义(P0.05)。结论毛果芸香碱联合拉坦前列素治疗原发性急性闭角型青光眼疗效显著,可明显改善视力,有效提高视野,降低眼压,安全性高,具有一定的临床推广应用价值。